Positive results from a trial of Eli Lilly’s (NYSE: LLY) monoclonal antibody mirikizumab raise the prospect of further competition in the gastrointestinal disorder space.
The anti-interleukin (IL_-23p19 antibody is being developed for moderate to severe ulcerative colitis (UC), and data now show the Phase III LUCENT-1 study met its goals in this indication.
Lilly’s competition is already racing ahead, with AbbVie’s (NYSE: ABBV) anti-IL-23 antibody Skyrizi (risankizumab‐rzaa) and Johnson & Johnson’s (NYSE: JNJ) Stelara (ustekinumab) making inroads in plaque psoriasis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze